AGP
APGE

Artia Global Partners’s Apogee Therapeutics APGE Stock Holding History

Artia Global Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,886
Closed -$495K – 50
2026
Q1 		$495K Buy
+5,886
New +$427K 0.1% 48
2024
Q3 		– Sell
-58,400
Closed -$2.3M – 46
2024
Q2 		$2.3M Sell
58,400
-3,190
-5% -$155K 0.44% 26
2024
Q1 		$4.09M Buy
61,590
+51,209
+493% +$2.24M 0.82% 17
2023
Q4 		$290K Buy
+10,381
New +$208K 0.08% 29

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Artia Global Partners's APGE Position: Q2 2026 in Review

Artia Global Partners sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 5,886 shares — an estimated $495K sold.

Artia Global Partners first reported a position in APGE in Q4 2023 and held it in 4 quarters. The position peaked at $4.09M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Artia Global Partners reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Artia Global Partners sold 5,886 Apogee Therapeutics shares in Q2 2026, an estimated $495K.
  • Artia Global Partners first reported a position in Apogee Therapeutics in Q4 2023 and held it in 4 quarters.
  • Artia Global Partners's Apogee Therapeutics position peaked at $4.09M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.